Pfizer beat consensus exp. in the Mrch period.
The EPS for 2016 are 1.72/1.85 $, on sales of 51/53 billion $.
We think that the split between the core human pharma and the rest of the Group probably could come in late 2016.
Strong financial position.
The EPS for 2016 are 1.72/1.85 $, on sales of 51/53 billion $.
We think that the split between the core human pharma and the rest of the Group probably could come in late 2016.
Strong financial position.
Transakcja zamknięta: osiągnięto wyznaczony cel
